Table 3.
Cell-mediated immune responses
| Antigen |
Control group |
E6 group |
E9 group |
L6 group |
L9 group |
|||||||||||
| Week 0 | Week 48 | P value | Week 0 | Week 48 | P value | Week 0 | Week 48 | P value | Week 0 | Week 48 | P value | Week 0 | Week 48 | P value | ||
| Lymphoproliferative response | ||||||||||||||||
| Capsid | Total n | 25 | 25 | 14 | 13 | 15 | 14 | 13 | 14 | 12 | 11 | |||||
| Positive (%) | 4 | 0 | ns | 7.1 | 15.4 | ns | 20 | 14.3 | ns | 38.5 | 7.1 | ns | 8.3 | 18.2 | ns | |
| SI1 | 1.2 ± 0.8 | 0.8 ± 0.5 | ns | 1.1 ± 0.6 | 1.2 ± 0.9 | ns | 1.8 ± 1.2 | 2.5 ± 3.4 | ns | 2.3 ± 2.0 | 1.5 ± 1.2 | ns | 1.5 ± 0.8 | 1.7 ± 1.8 | ns | |
| E2 | Total n | 25 | 23 | 13 | 9 | 14 | 10 | 13 | 10 | 12 | 9 | |||||
| Positive (%) | 16 | 8.7 | ns | 7.7 | 11.1 | ns | 21.4 | 0 | ns | 23.1 | 0 | ns | 13.3 | 0 | ns | |
| SI | 1.5 ± 1.8 | 1.6 ± 3.1 | ns | 0.9 ± 0.7 | 1.2 ± 1.2 | ns | 2.2 ± 2.2 | 0.6 ± 0.3 | 0.04 | 2.3 ± 2.4 | 1.1 ± 0.6 | ns | 1.4 ± 1.1 | 1.2 ± 0.8 | ns | |
| NS3 | Total n | 24 | 21 | 13 | 9 | 13 | 10 | 13 | 10 | 12 | 8 | |||||
| Positive (%) | 8.3 | 0 | ns | 7.7 | 11.1 | ns | 7.7 | 0 | ns | 30.8 | 0 | ns | 8.3 | 0 | ns | |
| SI | 1.2 ± 0.9 | 1.0 ± 0.6 | ns | 1.2 ± 0.8 | 2.0 ± 3.5 | ns | 1.7 ± 1.4 | 1.1 ± 0.4 | ns | 2.0 ± 1.3 | 0.9 ± 0.4 | 0.03 | 1.3 ± 0.8 | 1.1 ± 0.5 | ns | |
| IFN-γ ELISPOT response | ||||||||||||||||
| Capsid | Total n | 24 | 22 | 13 | 9 | 11 | 7 | 12 | 9 | 9 | 7 | |||||
| Positive (%) | 16.7 | 9.1 | ns | 23.1 | 0 | ns | 27.3 | 12.5 | ns | 8.3 | 27.3 | ns | 33.3 | 0 | - | |
| SFC | 151.4 ± 228.4 | 38.2 ± 67.3 | 0.003 | 232.9 ± 466.2 | 49.8 ± 94.1 | ns | 422.4 ± 731.7 | 50.5 ± 80.1 | ns | 120.9 ± 112.4 | 101.0 ± 89.5 | ns | 330.0 ± 214.7 | 116.0 ± 125.3 | ns | |
| E2 | Total n | 15 | 16 | 10 | 7 | 5 | 4 | 6 | 4 | 2 | 4 | |||||
| Positive (%) | 20 | 12.5 | ns | 10 | 0 | - | 0 | 0 | - | 0 | 20 | ns | 50 | 0 | - | |
| SFC | 84.6 ± 117.9 | 42.0 ± 82.4 | 0.040 | 96.8 ± 144.1 | 31.2 ± 54.8 | ns | 245.7 ± 409.4 | 3.9 ± 1.7 | ns | 19.9 ± 14.4 | 30.0 ± 33.6 | ns | 120.6 ± 73.9 | 23.3 ± 24.8 | ns | |
| NS3 | Total n | 17 | 12 | 9 | 4 | 1 | 4 | 7 | 3 | 4 | 3 | |||||
| Positive (%) | 15.4 | 8.3 | ns | 11.1 | 0 | - | 100 | 0 | ns | 100 | 0 | - | 25 | 0 | - | |
| SFC | 132.1 ± 259.7 | 52.0 ± 97.4 | 0.030 | 329.1 ± 452.3 | 2.5 ± 3.5 | ns | 110.8 ± 0.0 | 7.92 ± 10.7 | - | 31.3 ± 30.8 | 26.9 ± 23.5 | ns | 260.7 ± 315.7 | 15.2 ± 8.4 | ns | |
Data on number of positive samples are presented as percent of total evaluated samples. Stimulation index and spot forming cells data are presented as mean ± SD. Statistical values refer to time dependent differences in one group (week 0 vs week 48; P < 0.05, Wilcoxon signed rank test).
1
A statistically significant difference regarding core-specific lymphoproliferation was observed among the groups on week 0 (P = 0.04, Kruskal-Wallis test), but the multiple comparison test was not potent enough to indicate which of the groups accounted for the difference. SI: Stimulation index; ns: Not significant; SFC: Sport forming cells/106 cells.